AQXP - Aquinox Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.70
-0.02 (-0.14%)
As of 11:34AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close14.72
Open14.75
Bid14.57 x 900
Ask14.61 x 800
Day's Range14.29 - 14.75
52 Week Range10.02 - 16.90
Volume29,984
Avg. Volume91,376
Market Cap345.571M
Beta-17.57
PE Ratio (TTM)N/A
EPS (TTM)-2.41
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.25
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS

    -Trial Will Enroll Approximately 100 Male Subjects in the US and Canada-. VANCOUVER, British Columbia, June 11, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering ...

  • GlobeNewswirelast month

    Aquinox to Present at 2018 UBS Global Healthcare Conference

    VANCOUVER, British Columbia, May 16, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, ...

  • GlobeNewswirelast month

    Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

    Aquinox Pharmaceuticals, Inc. (AQXP) (“Aquinox”), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, and Astellas Pharma Inc. (TSE:4503) (“Astellas”) today announced an exclusive license agreement (“Agreement”) for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe. Under the Agreement, Astellas will have the exclusive right to research, develop, and commercialize rosiptor for all human diseases and conditions in Japan and additional countries in the Asia-Pacific region, including major markets such as South Korea, Australia, Taiwan, Indonesia, and Malaysia, but excluding China and India.

  • Associated Presslast month

    Aquinox: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 62 cents. Aquinox shares have climbed 11 percent since the beginning of the year. The stock has fallen 6.5 percent ...

  • GlobeNewswirelast month

    Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results

    VANCOUVER, British Columbia, May 08, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, ...

  • How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?
    Simply Wall St.2 months ago

    How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?

    The most recent earnings announcement Aquinox Pharmaceuticals Inc’s (NASDAQ:AQXP) released in December 2017 suggested company earnings became less negative compared to the previous year’s level – great news for investorsRead More...

  • GlobeNewswire2 months ago

    Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference

    VANCOUVER, British Columbia, May 02, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, ...

  • GlobeNewswire2 months ago

    Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference

    VANCOUVER, British Columbia, April 26, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory ...

  • ACCESSWIRE3 months ago

    Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%

    Stock Monitor: Aquinox Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free earnings report on Zoetis Inc. (NYSE: ZTS ). If you want access ...

  • Associated Press3 months ago

    Aquinox reports 4Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 69 cents. For the year, the company reported that its loss widened to $50.2 million, or $2.14 per share. Aquinox ...

  • ACCESSWIRE3 months ago

    Aquinox Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern ...

  • Reuters3 months ago

    Morning News Call - Canada, March 12

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/morning_News_Call/MNCGeneric_CA_03122018.pdf You can read Morning News Call Canada via TOPNEWS Canada page. ...

  • Comparing Cara Therapeutics’ Financial Performance
    Market Realist5 months ago

    Comparing Cara Therapeutics’ Financial Performance

    What's in Store for Cara Therapeutics in 2018?

  • Cara Therapeutics’ Collaboration Agreements
    Market Realist5 months ago

    Cara Therapeutics’ Collaboration Agreements

    What's in Store for Cara Therapeutics in 2018?

  • An Insight into Cara Therapeutics’ Drug Pipeline
    Market Realist5 months ago

    An Insight into Cara Therapeutics’ Drug Pipeline

    Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.

  • Analysts’ Recommendations for Cara Therapeutics in January 2018
    Market Realist5 months ago

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.